Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - victor+hruby
12
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
MC4R Selective Ligand for Obesity and Alzheimer’s Disease Prevention
This technology is a novel peptide that has been shown to be a potent MC4R selective antagonist. It is a potential therapeutic for cognitive loss and obesity. Background: The challenges of neurodegradation, Alzheimer’s disease, and obesity have been shown to have some similar molecular signatures that contribute to disease and have thus created...
Published: 3/12/2024
|
Inventor(s):
Minying Cai
,
Victor Hruby
Keywords(s):
Category(s):
Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences
,
Technology Classifications > Healthcare Portfolios > Diabetes, Metabolism, Endocrinology & Obesity
,
Technology Classifications > Life Sciences > Therapeutics
,
Technology Classifications > Life Sciences > Small Molecules
Selective Melanotropin 4 Ligands for Neurodegenerative Diseases
This technology is the development of ligands that selectively bind to the Melanocortin 3 Receptor (MC3R) and Melanocortin 4 Receptor (MC4R) and modulate receptor activity for neurodegenerative diseases. The melanocortin receptor ligand is bound to an MC3R and/or MC4R selective moiety, which allows the complex to cross the blood brain barrier. The ligand-moiety...
Published: 3/12/2024
|
Inventor(s):
Minying Cai
,
Victor Hruby
Keywords(s):
Category(s):
Technology Classifications > Life Sciences > Small Molecules
,
Technology Classifications > Life Sciences > Therapeutics
Selective Melanotropin Ligands for Neurodegenerative Diseases including Parkinson's
This technology involves administering an α-melanocyte-stimulating hormone through a carrier to selective melanotropin receptor ligands to treat neurodegenerative diseases. Specifically, this technology allows melanotropin to be administered through either one or both, the melanocortin 3 receptor (MC3R) and melanocortin 4 receptor (MC4R). Background: There...
Published: 3/12/2024
|
Inventor(s):
Minying Cai
,
Victor Hruby
Keywords(s):
Category(s):
Technology Classifications > Healthcare Portfolios > Neurology
,
Technology Classifications > Life Sciences > Drug Delivery
Modulators of Melanocortin Receptors for the Treatment of Depression and Anxiety
This invention is the use of the melanocortin 5 receptor (MC5R) ligand to treat depressive and anxiety disorders. MC5R antagonism is the proposed mechanism of action. Background: Depression and anxiety often have similar treatment, but experiencing the full effects of current pharmacotherapy can range from weeks to months. Antidepressants and anxiolytics...
Published: 3/12/2024
|
Inventor(s):
Victor Hruby
,
Minying Cai
Keywords(s):
Category(s):
Technology Classifications > Healthcare Portfolios > Neurology > Mental Health
,
Technology Classifications > Life Sciences > Therapeutics
Method for the Treatment of Depression and Anxiety
This technology relates to a modified version of SHU9119, a peptide chain that is known to interact with Melanocortin. This modified version of SHU9119 can antagonize the Melanocortin 5 Receptor (MC5R), potentially enabling rapidly-acting drugs to target these receptors and provide therapeutic relief for those suffering from depression and other mood...
Published: 3/12/2024
|
Inventor(s):
Victor Hruby
,
Minying Cai
,
Horst Kessler
Keywords(s):
Category(s):
Technology Classifications > Life Sciences > Therapeutics
Methods for the Treatment of Central Nervous System (CNS) Disorders and Mood Disorders
This technology is a modified version of SHU9119, a peptide chain that is known to interact with Melanocortin Receptors. This modified version of SHU9119 can antagonize a Melanocortin 5 Receptor, allowing rapidly acting drugs to target these receptors and provide therapeutic relief for those suffering from depression and other mood disorders. Background: Current...
Published: 3/12/2024
|
Inventor(s):
Victor Hruby
,
Minying Cai
Keywords(s):
Category(s):
Technology Classifications > Life Sciences > Therapeutics
Novel Modulators of Melanocortin Receptors for the Treatment of Depression and Anxiety
This technology describes a cyclic peptide modification that allows for antagonistic binding toward melanocortin 5 receptor (MC5R). Evidence links this receptor to depression and mood disorders, allowing the invention to effectively treat certain mental disorders. Background: SHU9119 is a peptide chain that is known to interact with melanocortin...
Published: 3/12/2024
|
Inventor(s):
Victor Hruby
,
Minying Cai
Keywords(s):
Category(s):
Technology Classifications > Life Sciences > Therapeutics
Method for the Treatment of Depression
This invention involves utilizing a composition, PG-20N, to treat depression or anxiety. It is specifically designed to treat conditions with a selective melanocortin 5 (MC5R) antagonist. Melanocortins exert many biological activities in the brain including control of feeding, grooming, hyperalgesia, social and sexual behaviors, central regulation of...
Published: 3/12/2024
|
Inventor(s):
Victor Hruby
,
Minying Cai
,
Caurnel Morgan
Keywords(s):
Category(s):
Technology Classifications > Life Sciences > Small Molecules
Conjugation of the MCR1 Ligand with Cytotoxic Drugs for Targeted Melanoma Therapy
University of Arizona researchers have developed a drug composition and method of cancer treatment using chemotherapeutics linked to ligands selective for uptake by melanocortin 1 receptors (MC1R) in MC1R-overexpressing melanoma. This development targets melanoma, and may be used with a wide range of cytotoxic drugs, to selectively deliver a toxic payload...
Published: 10/23/2025
|
Inventor(s):
Minying Cai
,
Victor Hruby
,
Yang Zhou
Keywords(s):
Category(s):
Technology Classifications > Healthcare Portfolios > Dermatology
,
Technology Classifications > Healthcare Portfolios > Oncology
Application of Neuroprotective Beta Amyloid Core Peptides and Peptidomimetic Derivatives to the Treatment of Alzheimer's Disease
Despite a notable role for amyloid and amyloid plaques in Alzheimer's disease, treatments aimed at lowering the levels of beta amyloid or disrupting amyloid plaques have had little or no impact on the disease. Using a novel approach, a core hexapeptide fragment derived from beta amyloid has been shown to be protective at the synaptic, cellular and behavioral...
Published: 7/19/2022
|
Inventor(s):
Robert Nichols
,
Kelly Forest
,
Victor Hruby
Keywords(s):
Healthcare:Alzheimer’s Disease
,
Healthcare:Neurological Disorders
,
Research Tool:Cell Culture & Media
,
Research Tool:Cell Line
,
Screening:Cellular Assay
,
Therapeutic:Disease Model
,
Therapeutic:Drug Delivery
,
Therapeutic:Peptides
Category(s):
Therapeutic
1
2